Literature DB >> 34155350

The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.

Ingrid Ferreira1,2, Alastair Droop1, Olivia Edwards1, Kim Wong1, Victoria Harle1, Omar Habeeb3, Deepa Gharpuray-Pandit4, Joseph Houghton5, Katharina Wiedemeyer6,7, Thomas Mentzel8, Steven D Billings9, Jennifer S Ko9, Laszlo Füzesi10, Kathleen Mulholland11, Ivana Kuzmic Prusac12, Bernadette Liegl-Atzwanger13, Nicolas de Saint Aubain14, Helen Caldwell15, Laura Riva1, Louise van der Weyden1, Mark J Arends15, Thomas Brenn16,17,18, David J Adams1.   

Abstract

Dedifferentiation and transdifferentiation are rare and only poorly understood phenomena in cutaneous melanoma. To study this disease more comprehensively we have retrieved 11 primary cutaneous melanomas from our pathology archives showing biphasic features characterized by a conventional melanoma and additional areas of de-/trans-differentiation as defined by a lack of immunohistochemical expression of all conventional melanocytic markers (S-100 protein, SOX10, Melan-A, and HMB-45). The clinical, histologic, and immunohistochemical findings were recorded and follow-up was obtained. The patients were mostly elderly (median: 81 years; range: 42-86 years) without significant gender predilection, and the sun-exposed skin of the head and neck area was most commonly affected. The tumors were deeply invasive with a mean depth of 7 mm (range: 4-80 mm). The dedifferentiated component showed atypical fibroxanthoma-like features in the majority of cases (7), while additional rhabdomyosarcomatous and epithelial transdifferentiation was noted histologically and/or immunohistochemically in two tumors each. The background conventional melanoma component was of desmoplastic (4), superficial spreading (3), nodular (2), lentigo maligna (1), or spindle cell (1) types. For the seven patients with available follow-up data (median follow-up period of 25 months; range: 8-36 months), two died from their disease, and three developed metastases. Next-generation sequencing of the cohort revealed somatic mutations of established melanoma drivers including mainly NF1 mutations (5) in the conventional component, which was also detected in the corresponding de-/trans-differentiated component. In summary, the diagnosis of primary cutaneous de-/trans-differentiated melanoma is challenging and depends on the morphologic identification of conventional melanoma. Molecular analysis is diagnostically helpful as the mutated gene profile is shared between the conventional and de-/trans-differentiated components. Importantly, de-/trans-differentiation does not appear to confer a more aggressive behavior.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34155350     DOI: 10.1038/s41379-021-00857-z

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  65 in total

1.  Rhabdomyoblastic differentiation in malignant melanoma in adults: report of 2 cases.

Authors:  Deepa Gharpuray-Pandit; John Coyne; Brian Eyden; S Sankar Banerjee
Journal:  Int J Surg Pathol       Date:  2007-01       Impact factor: 1.271

2.  Collision tumour: atypical fibroxanthoma and invasive melanoma.

Authors:  M J Wilsher
Journal:  Pathology       Date:  2009       Impact factor: 5.306

3.  Desmoplastic melanoma with sarcomatoid dedifferentiation.

Authors:  Maija Kiuru; Gregory McDermott; Michael Berger; Allan C Halpern; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

4.  Dedifferentiated and Undifferentiated Melanomas: Report of 35 New Cases With Literature Review and Proposal of Diagnostic Criteria.

Authors:  Abbas Agaimy; Robert Stoehr; Annkathrin Hornung; Judith Popp; Michael Erdmann; Lucie Heinzerling; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2021-02-01       Impact factor: 6.394

5.  Melanoma with rhabdomyosarcomatous differentiation: two further cases of a rare pathologic pitfall.

Authors:  Patrick Shenjere; Cyril Fisher; Ramzi Rajab; Lipsta Patnaik; Steve Hazell; Khin Thway
Journal:  Int J Surg Pathol       Date:  2014-04-29       Impact factor: 1.271

6.  Whole-genome landscapes of major melanoma subtypes.

Authors:  Nicholas K Hayward; James S Wilmott; Nicola Waddell; Peter A Johansson; Matthew A Field; Katia Nones; Ann-Marie Patch; Hojabr Kakavand; Ludmil B Alexandrov; Hazel Burke; Valerie Jakrot; Stephen Kazakoff; Oliver Holmes; Conrad Leonard; Radhakrishnan Sabarinathan; Loris Mularoni; Scott Wood; Qinying Xu; Nick Waddell; Varsha Tembe; Gulietta M Pupo; Ricardo De Paoli-Iseppi; Ricardo E Vilain; Ping Shang; Loretta M S Lau; Rebecca A Dagg; Sarah-Jane Schramm; Antonia Pritchard; Ken Dutton-Regester; Felicity Newell; Anna Fitzgerald; Catherine A Shang; Sean M Grimmond; Hilda A Pickett; Jean Y Yang; Jonathan R Stretch; Andreas Behren; Richard F Kefford; Peter Hersey; Georgina V Long; Jonathan Cebon; Mark Shackleton; Andrew J Spillane; Robyn P M Saw; Núria López-Bigas; John V Pearson; John F Thompson; Richard A Scolyer; Graham J Mann
Journal:  Nature       Date:  2017-05-03       Impact factor: 49.962

7.  Malignant Melanoma With Rhabdomyosarcomatous Differentiation: A Case Report.

Authors:  Nina K Antonov; George W Niedt
Journal:  Am J Dermatopathol       Date:  2016-06       Impact factor: 1.533

Review 8.  Living on the Edge: Diagnosing Sarcomatoid Melanoma Using Histopathologic Cues at the Edge of a Dedifferentiated Tumor: A Report of 2 Cases and Review of the Literature.

Authors:  Emily M Erstine; Michael T Tetzlaff; Jennifer S Ko; Victor G Prieto; Alison L Cheah; Steven D Billings
Journal:  Am J Dermatopathol       Date:  2017-08       Impact factor: 1.533

9.  Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.

Authors:  Abbas Agaimy; Katja Specht; Robert Stoehr; Thomas Lorey; Bruno Märkl; Gerald Niedobitek; Melanie Straub; Thomas Hager; Anna-Carinna Reis; Bastian Schilling; Regine Schneider-Stock; Arndt Hartmann; Thomas Mentzel
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

Review 10.  Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.

Authors:  Roy Rabbie; Peter Ferguson; Christian Molina-Aguilar; David J Adams; Carla D Robles-Espinoza
Journal:  J Pathol       Date:  2019-02-15       Impact factor: 7.996

View more
  1 in total

1.  Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?

Authors:  Hui Liu; Qi Shen; Chung-Che Chang; Shimin Hu
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.